As an example, one responder, an 87-year-old woman with poorly differentiated colon adenocarcinoma and peritoneal carcinomatosis with anaplastic lymphoma kinase (ALK)–striatin calmodulin-binding protein (STRN) fusion (as well as genetic alterations in KRAS, serine/threonine kinase 11 [STK11], and TP53), was treated with ceritinib [7]. Here, KRAS is linked to colon adenocarcinoma.